# PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

Source: https://onco.cc/trials/nct05390710/  
OnCo record `nct05390710` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Afuresertib run by Laekna Limited, completed.

## Summary

PhI to Solid Tumors and PhII to Locally Advanced or mTNBC is a phase 1 interventional study registered as NCT05390710 by Laekna Limited, with 21 participants enrolled, started 2021-06-12, primary completion reached 2023-12-11. Conditions recorded: Solid Tumor, TNBC - Triple-Negative Breast Cancer. Interventions recorded: LAE005 + Afuresertib + Nab-Paclitaxel.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05390710
- Phase: 1
- Setting: A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBC
- Sponsor: Laekna Limited
- Enrolled: 21

## Sources

- ClinicalTrials.gov NCT05390710: https://clinicaltrials.gov/study/NCT05390710

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Afuresertib](https://onco.cc/drugs/afuresertib/)
- companies: [Laekna Therapeutics](https://onco.cc/companies/laekna-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05390710.json